General Biotechnology

Drug Patent Expirations in September 2010

September 1, 2010

Drug Patent Expirations in September 2010 *Drugs may be covered by multiple patents Tradename Applicant Generic Name Patent Number Patent Expiration MUSE Vivus alprostadil 5,242,391 Sep 7, 2010 ADVAIR DISKUS 100/50 Glaxosmithkline fluticasone propionate; salmeterol xinafoate RE40045 Sep 7, 2010 ADVAIR DISKUS 500/50 Glaxosmithkline fluticasone propionate; salmeterol xinafoate RE40045 Sep 7, 2010 ZINECARD Pharmacia And [...]

Read the full article →

Orphan Drug Report

August 27, 2010

I’ve posted a new Orphan Drug Report at thinkPharm.com. This new report complements the Drug Patent Inventor Report, and profiles pharmaceutical drugs with FDA Orphan Drug Exclusivity. The Orphan Drug Report includes: The tradename, applicant, ingredient, and Orphan exclusivity expiration dates for each Orphan Drug Details on each NDA and product number, including Dosage, Strength, [...]

Read the full article →

Coming soon – Biotechnology Entrepreneurship: From Science to Solutions

August 24, 2010

Coming soon, a book by frequent Michael L. Salgaller, PhD. In this new book — Biotechnology Entrepreneurship: From Science to Solutions — Michael combines the voices of a diverse set of industry insiders with extensive experience in biotechnology commercialization to prepares nascent founders, managers, investors, and other biotechnology company stakeholders to position themselves and their [...]

Read the full article →

Synthetic Biology: Revolutionary or Evolutionary

August 23, 2010

Synthetic biology has been hailed as a revolution in biotechnology, enabling bold new possibilities in areas such as energy production, medicines, and other applications. But, is it really revolutionary, or just a new tool? With our current knowledge of the structure and function of proteins, the ability for de novo engineering is relatively limited. The [...]

Read the full article →

Drug inventor report profiles individuals, US states, and countries leading pharmaceutical innovation

August 16, 2010

A new report from DrugPatentWatch.com profiles the leading researchers, US states, and countries responsible for drugs approved over the past ten years. The report features: Top Inventors Which inventors were granted the most patents? Patents per Inventor The patents awarded to each inventor Approved Drugs per Inventor The approved drugs protected by each inventor’s patents [...]

Read the full article →

Drug Patent Expirations in August 2010

August 2, 2010

Drug Patent Expirations in August 2010 Tradename Applicant Generic Name Patent Number Patent Expiration ATRIPLA Gilead efavirenz; emtricitabine; tenofovir disoproxil fumarate 7,402,588*PED Aug 1, 2010 TRUVADA Gilead emtricitabine; tenofovir disoproxil fumarate 7,402,588*PED Aug 1, 2010 EMTRIVA Gilead emtricitabine 7,402,588*PED Aug 1, 2010 GENESA Gensia Automedics arbutamine hydrochloride 5,234,404 Aug 10, 2010 PREVPAC Takeda Pharms Na [...]

Read the full article →

Synthetic Biology: What’s the Agenda?

July 29, 2010

The Center for Policy on Emerging Technologies, where I am on the board of directors, is hosting an Emerging Technologies Roundtable: August 13, 2010 – “Synthetic Biology: What’s the Agenda?” Synthetic biology has hit the headlines yet again. The J. Craig Venter Institute’s recent dramatic announcement led to a replay of President Clinton’s urgent request [...]

Read the full article →

Biotechnology and Business Publishing Opportunities: Blog posts, Journal Articles, Books, and Magazines

July 26, 2010

Do you have an idea for an article, a blog post, a book, or a magazine article? In addition to publishing BiotechBlog, I also manage other publishing opportunities. Check out my publishing opportunities page for an overview of opportunities.

Read the full article →

Journal of Commercial Biotechnology — July 2010 issue now available

July 22, 2010

The July 2010 issue of the Journal of Commercial Biotechnology is now available. The links below will take you to the abstract for each paper: Volume 16, Issue 3 Increasing clarity (free full-text) Yali Friedman Personalized medicine and oncology: A commentary and key questions Robert Freeman Market access – An essential investment before drug launch [...]

Read the full article →

Building the Case for Biotechnology: Management Case Studies in Science, Laws, Regulations, Politics, and Business

July 12, 2010

Now available, a new textbook from Logos Press: Building the Case for Biotechnology: Management Case Studies in Science, Laws, Regulations, Politics, and Business Available from Amazon.com and bookstores everywhere. Mark J. Ahn, Michael A. Alvarez, Arlen D. Meyers, Anne S. York, editors Foreword by G. Steven Burrill First Edition, July 2010 Perfect Bound, 416 pages, [...]

Read the full article →

← Previous Entries